While cautioning that it's still early days, experts said the data - especially those showing much lower toxicity - raise the prospect that the therapy could replace autologous CAR-Ts, if its efficacy remains the same.
The Phase I study is planned to enroll 24 patients with relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma and will be run under Allogene's collaboration with Servier.
The layout of your phlebotomy station can significantly impact efficiency. A well-thought-out setup ensures that every tool is within reach, minimizing unnecessary movement and reducing patient wait times.